Hester Biosciences reported a significant 99% surge in consolidated profit after tax for FY26, reaching INR 574.84 million. The company recommended a dividend of INR 11 per share. Strong performance in Poultry Healthcare offset challenges in Animal Healthcare due to tender delays.
Hester Biosciences Reports Stellar FY26 Profit Growth, Proposes Dividend
Consolidated Profit After Tax (PAT) surged by 99% to INR 574.84 million in FY26. Standalone PAT grew by 64% to INR 521.00 million.
Reader Takeaway: Strong profit growth driven by operational efficiencies and Poultry Healthcare, balanced by Animal Healthcare tender delays.
